RESUMO
Objective:To investigate the clinical efficacy and safety of anlotinib combined with docetaxel for the treatment of advanced non-small cell lung cancer.Methods:A total of 118 patients with advanced non-small cell lung cancer who received treatment in Jinhua Guangfu Cancer Hospital from March 2018 to June 2019 were included in this study. They were randomly assigned to receive treatment with either anlotinib combined with docetaxel (study group, n = 59) or docetaxel alone (control group, n = 59) for two treatment courses. Clinical efficacy, progression-free survival, 1-year survival rate, and adverse drug reactions were compared between the study and control groups. Results:There was no significant difference in the objective remission rate between the two groups (22.03% vs. 32.20%, χ2 = 1.544, P = 0.214). The disease control rate in the study group was significantly higher than that in the control group (88.14% vs. 69.49%, χ2 = 6.141, P = 0.013). Progression-free survival in the study group was significantly longer than that in the control group [6.92 months (95% CI: 3.83-9.54 months) vs. 3.84 months (95% CI: 2.08-6.17 months), χ2 = 5.934, P = 0.019). The 1-year survival rate in the study group was significantly higher than that in the control group [52.47% (31/59) vs. 32.20% (19/59), χ2 = 4.998, P = 0.025]. During the treatment, the proportion of patients having leucopenia, erythropenia, gastrointestinal adverse reactions and abnormal liver and kidney function in the study group was 20.34%, 13.56%, 28.81% and 5.08%, respectively, which was significantly higher than 16.95%, 10.17%, 23.73% and 3.39%, respectively in the control group ( χ2 = 0.211-0.835, P = 0.361-0.646). Conclusion:Arotinib combined with docetaxel can effectively inhibit the progression of non-small cell lung cancer, prolong the progression-free survival, increase the 1-year survival rate, and does not increase adverse drug reactions.
RESUMO
Objective To investigate the clinical effect of milrinone injection combined therapy in patients with cor pulmonale complicated with respiratory failure and observe the effect of milrinone on blood gas index, blood viscosity and pulmonary arterial pressure.Methods The clinical data of 100 patients with cor pulmonale complicated with respiratory failure were retrospectively analyzed from April 2014 to April 2016.Among them, 50 cases were treated with conventional oxygen therapy, diuretic, asthma and anti-infection treatment.In the control group, 50 cases were treated with milrinone injection as the treatment group.The clinical curative effect and adverse reaction were analyzed.The blood gas analysis index, blood viscosity and pulmonary arterial pressure were measured before and after the treatment.The sputum normal and cyanosis, cough, wet rales and edema time were recorded in the two groups.Results The total effective rate of the treatment group was 92.0%, which was significantly higher than that of the control group 70.0%(P <0.05).After treatment, the hemorheological indexes and blood gas analysis indexes of the two groups improved significantly, However, the improvement of the indicators of the treatment group were significantly better than the control group (P<0.05).The pulmonary arterial pressure in the treatment group was (18.36 ±7.38) mmHg, which was significantly lower than that in the control group (23.79 ±6.14) mmHg (P<0.05); After treatment, the sputum normal and cyanosis in the treatment group, cough, wet rales, edema time were significantly shorter than the control group ( P <0.05 ) .No significant adverse effects were observed in both groups during the treatment.Conclusion The use of milrinone injection comprehensive treatment of pulmonary heart disease with respiratory failure in patients with significant efficacy and safety , but also can help improve blood viscosity and blood gas analysis indicators, reduce pulmonary artery pressure, better promote the rehabilitation of patients.
